PV Bulletin

Dexcom G7 Sensor Lot Recall – Unauthorized Distribution of Non-Conforming Lots in Canada

Two lots of Dexcom G7 Sensor (1-Pack) distributed in Canada by an unauthorized third party despite being intended for destruction due to non-conformance.

Primary source: Health Canada

PV Impact Brief

Urgency: HighConfidence: high

What changed

Health Canada published a recall alert for two unauthorized lots of Dexcom G7 Sensor distributed in Canada.

Why it matters

Patients using sensors from these lots may experience inaccurate glucose readings, leading to potential harm from incorrect insulin dosing.

Action needed

Identify and quarantine products from lots 1725204004 and 1725069002; contact patients who received sensors from these lots; report adverse events if any.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

as needed

Regulatory action details

Action type
Medical Device Recall
Publication date
2026-06-03
Safety issue
Recall due to unauthorized device issues or quality defects identified in Canada.

Affected products

  • Dexcom G7 Sensor 1 Pack
    Dexcom, Inc.

PV internal implications

Stop using the device if advised and contact the manufacturer for replacement or further guidance.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 3, 2026

Full briefing

Practical implication

Identify and quarantine products from lots 1725204004 and 1725069002; contact patients who received sensors from these lots; report adverse events if any.

Health Canada issued an alert for two lots of Dexcom G7 Sensor (lot #1725204004 and lot #1725069002) that were diverted from destruction and sold through unauthorized channels. The sensors did not meet Dexcom's product standards and may pose a safety risk.

What changed: Health Canada published a recall alert for two unauthorized lots of Dexcom G7 Sensor distributed in Canada.

Why it matters: Patients using sensors from these lots may experience inaccurate glucose readings, leading to potential harm from incorrect insulin dosing.

Practical implication: Identify and quarantine products from lots 1725204004 and 1725069002; contact patients who received sensors from these lots; report adverse events if any.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Health Canada#Safety Signal#Safety Signals#firecrawl-agent#regulatory-extraction#Health Product Recall

Related updates for your role

publicFDA · USA · Updated Aug 28, 2026

FDA Approves Mimrylo for Polycythemia Vera Treatment

Urgency: High

Patients will be treated with an initial dose of 19 mg of Mimrylo, administered weekly, with careful monitoring to maintain hematocrit levels below 45%. The operation of post-marketing surveillance will be affected due to the introduction of this new drug.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicMHRA · UK · Updated Aug 28, 2026

Record Ketamine Seizures Indicate Safety Concerns

Urgency: High

Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEMA · European Union · Updated Aug 28, 2026

PSUSA/00001088/202512 - Safety Update Amendments for Dimenhydrinate

Urgency: High

Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Aug 28, 2026

Choline Salicylate PSUSA/00000732/202512 - Safety Update Assessment

Urgency: High

Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward